Antihypertensive pharmacogenetic effect of fibrinogen-beta variant-455G>A on cardiovascular disease, end-stage renal disease, and mortality: The GenHAT study
Amy I. Lynch, Eric Boerwinkle, Barry R. Davis, Charles E. Ford, John H Eckfeldt, Catherine Leiendecker-Foster, Donna K. Arnett
Dive into the research topics of 'Antihypertensive pharmacogenetic effect of fibrinogen-beta variant-455G>A on cardiovascular disease, end-stage renal disease, and mortality: The GenHAT study'. Together they form a unique fingerprint.